Scholarlink

Background <p>Androgen receptor (AR) mutations in prostate cancer mainly cluster in the ligand binding domain (LBD), leading to therapy resistance. However, the biological role of AR in gastric cancer (GC) remains to be explored. We identified the A32C (p.Y11S) mutation was located in NTD and promoted the malignant progression of GC.</p> Methods <p>We analyzed 33 kinds of tumors in TCGA database and verified in 65 GC cases. Biological function analysis included proliferation, apoptosis and migration assays. The mechanism was studied by transcriptome map analysis, co-immunoprecipitation and drug inhibition with TAE226 in vitro and in liver metastasis models.</p> Results <p>AR A32C mutation significantly enhanced proliferation, anti-apoptotic capacity and G1/S phase transition ability, compared with wild-type AR. The substitution of Y11S site enhanced the binding affinity between AR and YWHAZ, thus establishing a cytoplasmic scaffold, which can spontaneously activate the FAK-PXN axis and downstream PI3K-AKT/ERK pathways. Knockdown of YWHAZ or inhibition of FAK rescued the malignant phenotype. In vivo, MT-AR cells exhibited higher hepatic colonization ability than wild-type cells, and the high activity of FAK persisted in metastatic lesions.</p> Conclusion <p>The AR A32C mutation is a previously unrecognized oncogenic driver, which can promote the metastasis of GC though YWHAZ mediated ligand independent FAK activation mechanism. These findings extend the research scope of AR mutation biology beyond hormone dependent cancers, and establish that FAK inhibitors based on AR mutation status are suitable for the treatment of AR mutant GC as a precision therapy.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Novel androgen receptor N-terminal mutation drives gastric cancer metastasis via YWHAZ-mediated FAK pathway activation

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年7月30日

查看全文
  • Tianru Ben,
  • Lingyu Zhou,
  • Zonghao Liu,
  • Xiang Jiao,
  • Linlin Gao,
  • Nan Xia

摘要

Background

Androgen receptor (AR) mutations in prostate cancer mainly cluster in the ligand binding domain (LBD), leading to therapy resistance. However, the biological role of AR in gastric cancer (GC) remains to be explored. We identified the A32C (p.Y11S) mutation was located in NTD and promoted the malignant progression of GC.

Methods

We analyzed 33 kinds of tumors in TCGA database and verified in 65 GC cases. Biological function analysis included proliferation, apoptosis and migration assays. The mechanism was studied by transcriptome map analysis, co-immunoprecipitation and drug inhibition with TAE226 in vitro and in liver metastasis models.

Results

AR A32C mutation significantly enhanced proliferation, anti-apoptotic capacity and G1/S phase transition ability, compared with wild-type AR. The substitution of Y11S site enhanced the binding affinity between AR and YWHAZ, thus establishing a cytoplasmic scaffold, which can spontaneously activate the FAK-PXN axis and downstream PI3K-AKT/ERK pathways. Knockdown of YWHAZ or inhibition of FAK rescued the malignant phenotype. In vivo, MT-AR cells exhibited higher hepatic colonization ability than wild-type cells, and the high activity of FAK persisted in metastatic lesions.

Conclusion

The AR A32C mutation is a previously unrecognized oncogenic driver, which can promote the metastasis of GC though YWHAZ mediated ligand independent FAK activation mechanism. These findings extend the research scope of AR mutation biology beyond hormone dependent cancers, and establish that FAK inhibitors based on AR mutation status are suitable for the treatment of AR mutant GC as a precision therapy.